Events

Plenary discussion: ORPH-VAL Using best practice European principles in assessing the value of orphan medicines: Correcting the discrepancy between countries

14th nov 2017

How do these principles compare to the criteria that current countries use?
Opportunity for different European payers/HTAs to openly suggest what is realistic and why
Creating a harmonised and sustainable model adapted to rare diseases
How is it acceptable that each country has a different post marketing criteria?
What are the interests of payers and HTA bodies when considering how to improve access to rare disease therapies?